Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 9/20 | 0.51 |
| ▸ | IL1B | P01584 | 3/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12450471 | 0.85 | CASP1 (0.58) | CASP1IL1BELANE | |
| SCHEMBL12450850 | 0.79 | CASP1 (0.51) | CASP1IL1BPOLBMAPTKDM4E | |
| SCHEMBL12450847 | 0.78 | CASP1 (0.51) | CASP1IL1BF2PRSS1MAPT | |
| SCHEMBL12450870 | 0.77 | CASP1 (0.61) | CASP1IL1BF2PRSS1POLB | |
| SCHEMBL12946382 | 0.76 | CASP1 (0.56) | CASP1IL1BELANE | |
| SCHEMBL13197075 | 0.74 | CASP1 (0.60) | CASP1IL1BPOLBELANEKDM4E | |
| SCHEMBL10200776 | 0.74 | CASP1 (0.66) | CASP1IL1BF2PRSS1POLB | |
| SCHEMBL646080 | 0.74 | CASP1 (0.71) | CASP1IL1BF2PRSS1POLB | |
| SCHEMBL12450671 | 0.73 | CASP1 (0.68) | CASP1IL1BF2PRSS1POLB | |
| SCHEMBL14399361 | 0.70 | CASP1 (0.83) | CASP1IL1BF2PRSS1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1B, IL1A, IL1R1 | CASP1 5/4885IL1B 1/4885F2 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.